Ocular Therapeutix, Inc.

Contributing Author

Recent Articles by Ocular Therapeutix, Inc.

Nov-04	Ocular Therapeutix Reports Third Quarter 2025 Financial Results and Business Highlights OCUL GlobeNewswire
Nov-04	Ocular Therapeutix Achieves Target Randomization of 555 Subjects in SOL-R OCUL GlobeNewswire
Oct-28	Ocular Therapeutix to Report Third Quarter 2025 Financial Results on November 4, 2025 OCUL GlobeNewswire
Oct-07	Ocular Therapeutix to Participate in Upcoming Scientific Conferences OCUL GlobeNewswire
Sep-30	Ocular Therapeutix Announces Pricing of Underwritten Offering of Common Stock OCUL GlobeNewswire
Sep-30	Ocular Therapeutix Investor Day to Highlight Exceptional AXPAXLI Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint OCUL GlobeNewswire
Sep-08	Ocular Therapeutix to Host Investor Day on September 30, 2025 OCUL GlobeNewswire
Aug-27	Ocular Therapeutix to Participate in September Investor and Scientific Conferences OCUL GlobeNewswire
Aug-12	Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI in NPDR OCUL GlobeNewswire
Aug-05	Ocular Therapeutix Reports Second Quarter 2025 Financial Results and Business Highlights OCUL GlobeNewswire
Jul-29	Ocular Therapeutix to Report Second Quarter 2025 Financial Results on August 5, 2025 OCUL GlobeNewswire
Jul-22	Ocular Therapeutix to Participate in Upcoming Scientific Conferences OCUL GlobeNewswire
Jun-26	Ocular Therapeutix Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company OCUL GlobeNewswire
Jun-16	Ocular Therapeutix to Participate in Clinical Trials at the Summit (CTS) 2025 OCUL GlobeNewswire
May-28	Ocular Therapeutix To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI in Wet Age-Related Macular Degeneration OCUL GlobeNewswire
May-14	Ocular Therapeutix to Participate in Upcoming Investor Conferences OCUL GlobeNewswire
May-05	Ocular Therapeutix Reports First Quarter 2025 Results and Business Highlights OCUL GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.